Related Experiment Video
Updated: Jun 17, 2025
07:44
A Porcine Model of Acute Autologous Pulmonary Embolism
Published on: September 6, 2024
324
Post-pulmonary embolism syndrome: A reminder for clinicians
Leslie-Marisol Gonzalez-Hermosillo1, Guillermo Cueto-Robledo2,3,4, Dulce-Iliana Navarro-Vergara1,2
1Doctorate Program in Biomedical Sciences, Postgraduate Unit, National Autonomous University of Mexico, Mexico City, Mexico.
Asian Cardiovascular & Thoracic Annals
|August 13, 2024
Summary
Acute pulmonary embolism (APE) survivors often face long-term challenges like reduced function and quality of life. Aggressively treating high-risk patients may reduce mortality and prevent post-pulmonary embolism syndrome (PPES).
Area of Science:
- Cardiology
- Pulmonology
- Emergency Medicine
Background:
- Acute pulmonary embolism (APE) is a major cause of cardiovascular emergencies and mortality.
- Many APE survivors experience persistent functional limitations and reduced quality of life, termed post-pulmonary embolism syndrome (PPES).
- Current management primarily focuses on the acute event, potentially underestimating long-term sequelae.
Purpose of the Study:
- To highlight the long-term consequences of APE, including PPES.
- To emphasize the need for aggressive risk stratification and treatment in intermediate to high-risk APE patients.
- To advocate for a comprehensive approach to prevent and manage PPES.
Main Methods:
- Review of existing literature on APE outcomes and PPES.
- Analysis of risk factors and mortality associated with APE.
- Discussion of current treatment paradigms and potential interventions for PPES.
Main Results:
- Approximately 50% of APE survivors do not regain full function and suffer long-term quality of life reduction.
- High-risk and intermediate-risk APE cases concentrate most mortality and morbidity.
- Chronic thromboembolic pulmonary hypertension is a severe manifestation of unresolved APE.
Conclusions:
- Aggressive treatment of high-risk APE patients may reduce mortality and mitigate PPES.
- PPES is an under-recognized entity requiring systematic attention in management guidelines.
- Cardiopulmonary rehabilitation and comprehensive care are crucial for improving long-term outcomes in PPES patients.
Related Concept Videos
01:27Pneumothorax-II
129
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
129
01:30Pneumonia V: Nursing management and Prevention
1.9K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
1.9K
01:28Pleural Effusion II: Symptoms and Management
160
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
160
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
164
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
164
01:26Pneumothorax-I
186
A pneumothorax is a condition where air builds up in the space between the lung and the chest wall, causing the lung to collapse. This condition arises when air enters the space between the parietal and visceral pleura, disrupting the negative pressure essential for lung inflation. This can lead to a partial or complete collapse of the lung.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
186
01:30Pneumonia III: Complications and Assessment
193
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
193